8,046 reports of this reaction
4.8% of all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE reports
#7 most reported adverse reaction
TOOTH LOSS is the #7 most commonly reported adverse reaction for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, manufactured by Gilead Sciences, Inc. There are 8,046 FDA adverse event reports linking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE to TOOTH LOSS. This represents approximately 4.8% of all 167,978 adverse event reports for this drug.
Patients taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE who experience tooth loss should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TOOTH LOSS is moderately reported among EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE users, representing a notable but not dominant share of adverse events.
In addition to tooth loss, the following adverse reactions have been reported for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE:
The following drugs have also been linked to tooth loss in FDA adverse event reports:
TOOTH LOSS has been reported as an adverse event in 8,046 FDA reports for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TOOTH LOSS accounts for approximately 4.8% of all adverse event reports for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, making it a notable side effect.
If you experience tooth loss while taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.